Trial Profile
Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2023
Price :
$35
*
At a glance
- Drugs Axalimogene filolisbac (Primary) ; Epacadostat (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- Sponsors Advaxis; Ayala Pharmaceuticals; Incyte Corporation
- 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
- 08 Jan 2016 According to an Advaxis Immunotherapies media release, this trial is expected to commence in the first half of 2016.
- 01 Dec 2015 According to the Advaxis Inc. media release, the US FDA has granted orphan drug designation for axalimogene filolisbac in the treatment of cervical cancer.